What is the risk of thromboembolism and stroke in patients with atrial flutter?
The risk of thromboembolism and stroke in patients with atrial flutter has been evaluated in relatively few studies compared with AF. Clinical risk stratification for stroke is based on the CHA2DS2VASc-score. If diagnosis of AF or atrial flutter and intermediate (CHA2DS2VASc score = 1 in males and = 2 in females) or high risk (CHA2DS2VASc score 2 in males and 3 in females), monitoring of AHRE evolution (remote monitoring is advised), clinical follow-up for evaluating if AHRE >24 h and/or clinical AF develops, as well as changes in patient status/clinical profile (eg, heart failure) and individual considerations for prescription of OAC considering overall AHRE burden and AHRE >24 h, individual CHA2DS2VASc, predicted risk benefit of OAC (specifically risk of major bleeding) and patient preferences are recommended for clinical decision-making and follow-up.